SG11201708223QA - Compositions comprising a combination of an anti-pd-1 antibody and another antibody - Google Patents
Compositions comprising a combination of an anti-pd-1 antibody and another antibodyInfo
- Publication number
- SG11201708223QA SG11201708223QA SG11201708223QA SG11201708223QA SG11201708223QA SG 11201708223Q A SG11201708223Q A SG 11201708223QA SG 11201708223Q A SG11201708223Q A SG 11201708223QA SG 11201708223Q A SG11201708223Q A SG 11201708223QA SG 11201708223Q A SG11201708223Q A SG 11201708223QA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- compositions
- combination
- another
- another antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562149325P | 2015-04-17 | 2015-04-17 | |
US201562265268P | 2015-12-09 | 2015-12-09 | |
US201562269000P | 2015-12-17 | 2015-12-17 | |
US201662303855P | 2016-03-04 | 2016-03-04 | |
PCT/US2016/027913 WO2016168716A1 (en) | 2015-04-17 | 2016-04-15 | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201708223QA true SG11201708223QA (en) | 2017-11-29 |
Family
ID=55809254
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201708223QA SG11201708223QA (en) | 2015-04-17 | 2016-04-15 | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
SG10201912035YA SG10201912035YA (en) | 2015-04-17 | 2016-04-15 | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912035YA SG10201912035YA (en) | 2015-04-17 | 2016-04-15 | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
Country Status (32)
Country | Link |
---|---|
US (4) | US20160304607A1 (es) |
EP (2) | EP3738610A1 (es) |
JP (3) | JP6949718B2 (es) |
KR (1) | KR20170138477A (es) |
CN (2) | CN113577264A (es) |
AU (2) | AU2016249395B2 (es) |
BR (1) | BR112017021688A2 (es) |
CA (1) | CA2982839A1 (es) |
CL (1) | CL2017002636A1 (es) |
CO (1) | CO2017011536A2 (es) |
CY (1) | CY1123397T1 (es) |
DK (1) | DK3283107T3 (es) |
EA (1) | EA201792273A1 (es) |
ES (1) | ES2813580T3 (es) |
HK (1) | HK1247099A1 (es) |
HR (1) | HRP20201334T1 (es) |
HU (1) | HUE050894T2 (es) |
IL (2) | IL255072B (es) |
LT (1) | LT3283107T (es) |
MA (1) | MA53243A (es) |
MX (2) | MX2017013270A (es) |
MY (1) | MY188749A (es) |
PE (1) | PE20180394A1 (es) |
PH (1) | PH12017501774A1 (es) |
PL (1) | PL3283107T3 (es) |
PT (1) | PT3283107T (es) |
RS (1) | RS60753B1 (es) |
SG (2) | SG11201708223QA (es) |
SI (1) | SI3283107T1 (es) |
TN (1) | TN2017000440A1 (es) |
TW (3) | TW202335681A (es) |
WO (1) | WO2016168716A1 (es) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
EP2983661B1 (en) | 2013-04-09 | 2024-05-29 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
KR20230008255A (ko) | 2013-09-20 | 2023-01-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
DK3142751T3 (da) * | 2014-05-13 | 2019-10-14 | Medimmune Ltd | Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer |
MA47849A (fr) | 2014-05-28 | 2020-01-29 | Agenus Inc | Anticorps anti-gitr et leurs procédés d'utilisation |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
CN114099671A (zh) | 2014-08-12 | 2022-03-01 | 鳄鱼生物科学公司 | 利用抗cd40抗体的组合疗法 |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
CN113577264A (zh) | 2015-04-17 | 2021-11-02 | 百时美施贵宝公司 | 包含抗pd-1抗体和另外的抗体的组合的组合物 |
KR20170140316A (ko) | 2015-04-28 | 2017-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
WO2017011580A2 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
RS61532B1 (sr) * | 2015-07-14 | 2021-04-29 | Bristol Myers Squibb Co | Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) |
PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
EP3334763A4 (en) | 2015-08-11 | 2019-04-03 | Wuxi Biologics (Cayman) Inc. | NOVEL ANTI-PD-1 ANTIBODIES |
BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
UA121914C2 (uk) | 2015-11-18 | 2020-08-10 | Мерк Шарп І Доум Корп. | Молекула, що зв'язує pd1 і lag3 |
JP7089470B2 (ja) | 2015-12-02 | 2022-06-22 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
EP3399989B1 (en) | 2015-12-16 | 2023-08-09 | Merck Sharp & Dohme LLC | Anti-lag3 antibodies and antigen-binding fragments |
US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
AU2017266298B2 (en) | 2016-05-18 | 2024-01-04 | Boehringer Ingelheim International Gmbh | Anti PD-1 and anti-LAG3 antibodies for cancer treatment |
SG11201809669RA (en) | 2016-05-20 | 2018-11-29 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating agents with immunotherapies to treat cancer |
KR102257154B1 (ko) | 2016-09-19 | 2021-05-28 | 셀진 코포레이션 | Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법 |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
CA3046515A1 (en) * | 2016-12-08 | 2018-06-14 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
JP7110206B6 (ja) * | 2017-01-09 | 2022-08-25 | テサロ, インコーポレイテッド | 抗pd-1抗体を用いてがんを処置する方法 |
AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
EP3585812A1 (en) * | 2017-02-21 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Anti-pd-1 antibodies for treatment of lung cancer |
JP2020515542A (ja) * | 2017-03-23 | 2020-05-28 | ザ ジェネラル ホスピタル コーポレイション | Cxcr4/cxcr7の遮断およびヒトパピローマウイルス関連疾患の治療 |
MX2019010999A (es) * | 2017-03-29 | 2020-02-05 | Celgene Corp | Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas. |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
BR112019021680A2 (pt) | 2017-04-20 | 2020-05-12 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo-fármaco anti-cd25?? |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
TN2019000294A1 (en) * | 2017-05-02 | 2021-05-07 | Merck Sharp & Dohme | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
TW201842929A (zh) * | 2017-05-03 | 2018-12-16 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
US11685787B2 (en) | 2017-05-16 | 2023-06-27 | Bristol-Myers Squibb Company | Treatment of cancer with anti-GITR agonist antibodies |
EP3630179A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
AU2018277824A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
JP7145891B2 (ja) | 2017-06-14 | 2022-10-03 | アーデーセー セラピューティクス ソシエテ アノニム | 抗cd19 adcを投与するための投与レジメ |
US20190135905A1 (en) * | 2017-06-16 | 2019-05-09 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
TW202242403A (zh) * | 2017-08-18 | 2022-11-01 | 美商雷傑納榮製藥公司 | 使用影像毛細管等電聚焦以分析樣品基質中蛋白質變異體之方法 |
JP7437301B2 (ja) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | B7-h4抗体及びその使用方法 |
US20200206350A1 (en) * | 2017-09-05 | 2020-07-02 | Merck Sharp & Dohme Corp. | Compounds for reducing the viscosity of biological formulations |
JP2020532991A (ja) | 2017-09-07 | 2020-11-19 | オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド | プログラム細胞死タンパク質1に対する抗体 |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
MX2020004567A (es) * | 2017-11-06 | 2020-08-13 | Genentech Inc | Metodos diagnosticos y terapeuticos para el cancer. |
WO2019100052A2 (en) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
WO2019108951A1 (en) * | 2017-12-01 | 2019-06-06 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for inhibiting dhhc-type palmitoyltransferases for cancer treatment |
JP2021511372A (ja) * | 2018-01-16 | 2021-05-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Tim3に対する抗体で癌を処置する方法 |
EP3759142A1 (en) | 2018-03-02 | 2021-01-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
US20210155703A1 (en) * | 2018-04-04 | 2021-05-27 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
JP2021535187A (ja) * | 2018-06-15 | 2021-12-16 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | S−エクオールを用いた黒色腫の処置及び予防方法 |
JP2022512750A (ja) * | 2018-10-19 | 2022-02-07 | ブリストル-マイヤーズ スクイブ カンパニー | 黒色腫に対する併用療法 |
MX2021005266A (es) * | 2018-11-05 | 2021-06-18 | Merck Sharp & Dohme Llc | Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer. |
JP2022512851A (ja) * | 2018-11-05 | 2022-02-07 | メルク・シャープ・アンド・ドーム・コーポレーション | がんの処置のための抗tigit抗体の投薬レジメン |
JP2022512875A (ja) * | 2018-11-06 | 2022-02-07 | ゲンマブ エー/エス | 抗体製剤 |
BR112021008873A8 (pt) * | 2018-11-07 | 2023-04-11 | Merck Sharp & Dohme | Formulação |
WO2020097141A1 (en) | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
JP2022507253A (ja) | 2018-11-13 | 2022-01-18 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | チェックポイント分子に対する多重特異性結合性構築物およびその使用 |
JP7266108B2 (ja) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | 治療用抗体製剤 |
EP4008346A4 (en) * | 2019-07-18 | 2022-10-19 | Delta-Fly Pharma, Inc. | AGENT FOR INCREASING THE EFFECT OF AN ANTICONCER AGENT |
GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
US20230054413A1 (en) * | 2019-12-13 | 2023-02-23 | Samsung Bioepis Co., Ltd. | Stable anti-pd1 antibody pharmaceutical formulations |
EP4076385A1 (en) * | 2019-12-20 | 2022-10-26 | Formycon AG | Formulations of anti-pd1 antibodies |
US20230086099A1 (en) | 2020-01-30 | 2023-03-23 | Ona Therapeutics, S.L. | Combination therapy for treatment of cancer and cancer metastasis |
WO2021178657A1 (en) * | 2020-03-05 | 2021-09-10 | Merck Sharp & Dohme Corp. | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof |
KR20220151195A (ko) | 2020-03-06 | 2022-11-14 | 오엔에이 테라퓨틱스 에스.엘. | 항-cd36 항체 및 암을 치료하기 위한 이의 용도 |
JP2023522024A (ja) * | 2020-04-17 | 2023-05-26 | ディンフー バイオターゲット カンパニー リミテッド | Cd137と特異的に結合する製剤とその使用について |
BR112022025721A2 (pt) * | 2020-06-19 | 2023-01-03 | Sinocelltech Ltd | Formulação estável para anticorpo monoclonal anti-pd-1 recombinante |
WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
MX2022016218A (es) * | 2020-07-08 | 2023-03-31 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4. |
EP4008345A1 (en) * | 2020-12-03 | 2022-06-08 | Hexal AG | Novel formulations for antibodies |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
TW202308692A (zh) * | 2021-04-27 | 2023-03-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 包含帕博利珠單抗(pembrolizumab)的藥學組成物及其用途 |
EP4355780A1 (en) * | 2021-06-18 | 2024-04-24 | Alligator Bioscience AB | Novel combination therapies and uses thereof |
CN117915948A (zh) * | 2021-06-18 | 2024-04-19 | 建新公司 | 抗TGF-β抗体配制品及其用途 |
CA3220882A1 (en) * | 2021-07-02 | 2023-01-05 | David Scott Johnson | Anti-ctla-4 binding proteins and methods of use thereof |
IL309934A (en) | 2021-07-30 | 2024-03-01 | Ona Therapeutics S L | Anti-CD36 antibodies and their use for cancer treatment |
WO2023235847A1 (en) * | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6210669B1 (en) | 1996-10-11 | 2001-04-03 | Bristol-Myers Squibb Co. | Methods and compositions for immunomodulation |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
CA2370466C (en) | 1999-06-25 | 2011-02-08 | Sharon Erickson | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
US20050276823A1 (en) * | 2002-07-12 | 2005-12-15 | Cini John K | Methods and compositions for preventing oxidative degradation of proteins |
PL375144A1 (en) | 2002-07-30 | 2005-11-28 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
KR101444717B1 (ko) | 2003-07-02 | 2014-09-26 | 노보 노르디스크 에이/에스 | Nk 세포 활성을 조절하기 위한 조성물 및 방법 |
KR101299599B1 (ko) | 2003-07-24 | 2013-08-23 | 위니베르시따 데글리 스뚜디 디 뻬루지아 | Nk 세포 강화 화합물을 사용하여 치료용 항체의 효율을 높이는 방법 및 조성물 |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
PL2287195T3 (pl) | 2004-07-01 | 2019-10-31 | Novo Nordisk As | Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii |
EP1836225B1 (en) | 2005-01-06 | 2011-11-02 | Novo Nordisk A/S | Kir-binding agents and methods of use thereof |
US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
CN101193917A (zh) * | 2005-03-08 | 2008-06-04 | 法玛西雅厄普约翰有限责任公司 | 抗-MAdCAM抗体组合物 |
DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
RU2406760C3 (ru) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
CN101300272B (zh) | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
ES2627923T3 (es) | 2007-01-11 | 2017-08-01 | Novo Nordisk A/S | Anticuerpos anti-KIR, formulaciones y usos de los mismos |
JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用 |
SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
KR101554848B1 (ko) | 2007-10-01 | 2015-09-21 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
EP2224958A2 (en) | 2007-11-30 | 2010-09-08 | Bristol-Myers Squibb Company | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
US20090311187A1 (en) * | 2008-05-29 | 2009-12-17 | Bristol-Myers Squibb Company | Methods for predicting patient response to modulation of the Co-stimulatory pathway |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
SI2350129T1 (sl) | 2008-08-25 | 2015-11-30 | Amplimmune, Inc. | Sestavki PD-1 antagonistov in postopek njihove uporabe |
JP2012510468A (ja) * | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
EP2367553B1 (en) | 2008-12-05 | 2017-05-03 | Novo Nordisk A/S | Combination therapy to enhance nk cell mediated cytotoxicity |
CN104479018B (zh) | 2008-12-09 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
BR112012004823B1 (pt) | 2009-09-03 | 2021-11-30 | Merck Sharp & Dohme Corp | Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
NZ602892A (en) | 2010-04-13 | 2014-08-29 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
WO2012071411A2 (en) | 2010-11-22 | 2012-05-31 | Innate Pharma Sa | Nk cell modulating treatments and methods for treatment of hematological malignancies |
KR20140038382A (ko) | 2011-03-10 | 2014-03-28 | 프로벡투스 파마슈티컬스 인코포레이티드 | 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제 |
CN107854439A (zh) * | 2011-03-31 | 2018-03-30 | 默沙东公司 | 针对人程序性死亡受体pd‑1的抗体的稳定制剂和有关的治疗 |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
MX347514B (es) | 2011-05-25 | 2017-04-28 | Innate Pharma Sa | Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios. |
US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
KR102024957B1 (ko) | 2011-11-09 | 2019-09-24 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cxcr4 항체를 이용한 혈액 악성종양의 치료 |
EA036814B9 (ru) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение |
KR102193343B1 (ko) | 2012-05-15 | 2020-12-22 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
KR101566538B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Th17 세포 전환용 에피토프 및 이의 용도 |
IN2014KN00920A (es) * | 2012-06-21 | 2015-10-09 | Compugen Ltd | |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
CA2887027C (en) * | 2012-10-02 | 2021-11-16 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
WO2014209804A1 (en) * | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
KR101809151B1 (ko) * | 2013-07-18 | 2017-12-15 | (주)앗코스텍 | 키레놀 또는 희첨 추출물을 포함하는 골다공증 예방, 개선 또는 치료용 조성물 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
CA3080200A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
KR20230008255A (ko) | 2013-09-20 | 2023-01-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
MA47849A (fr) | 2014-05-28 | 2020-01-29 | Agenus Inc | Anticorps anti-gitr et leurs procédés d'utilisation |
DK3151921T3 (da) | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf |
CN113577264A (zh) | 2015-04-17 | 2021-11-02 | 百时美施贵宝公司 | 包含抗pd-1抗体和另外的抗体的组合的组合物 |
-
2016
- 2016-04-15 CN CN202110885081.8A patent/CN113577264A/zh active Pending
- 2016-04-15 MX MX2017013270A patent/MX2017013270A/es unknown
- 2016-04-15 PE PE2017002204A patent/PE20180394A1/es unknown
- 2016-04-15 AU AU2016249395A patent/AU2016249395B2/en active Active
- 2016-04-15 EA EA201792273A patent/EA201792273A1/ru unknown
- 2016-04-15 WO PCT/US2016/027913 patent/WO2016168716A1/en active Application Filing
- 2016-04-15 DK DK16718835.8T patent/DK3283107T3/da active
- 2016-04-15 EP EP20169527.7A patent/EP3738610A1/en active Pending
- 2016-04-15 SG SG11201708223QA patent/SG11201708223QA/en unknown
- 2016-04-15 HU HUE16718835A patent/HUE050894T2/hu unknown
- 2016-04-15 EP EP16718835.8A patent/EP3283107B1/en active Active
- 2016-04-15 LT LTEP16718835.8T patent/LT3283107T/lt unknown
- 2016-04-15 SI SI201630887T patent/SI3283107T1/sl unknown
- 2016-04-15 US US15/130,513 patent/US20160304607A1/en not_active Abandoned
- 2016-04-15 CA CA2982839A patent/CA2982839A1/en active Pending
- 2016-04-15 PL PL16718835T patent/PL3283107T3/pl unknown
- 2016-04-15 TN TNP/2017/000440A patent/TN2017000440A1/en unknown
- 2016-04-15 RS RS20201009A patent/RS60753B1/sr unknown
- 2016-04-15 KR KR1020177032904A patent/KR20170138477A/ko not_active Application Discontinuation
- 2016-04-15 ES ES16718835T patent/ES2813580T3/es active Active
- 2016-04-15 JP JP2017554282A patent/JP6949718B2/ja active Active
- 2016-04-15 CN CN201680035347.7A patent/CN107743401B/zh active Active
- 2016-04-15 BR BR112017021688-4A patent/BR112017021688A2/pt active Search and Examination
- 2016-04-15 MA MA053243A patent/MA53243A/fr unknown
- 2016-04-15 SG SG10201912035YA patent/SG10201912035YA/en unknown
- 2016-04-15 MY MYPI2017703912A patent/MY188749A/en unknown
- 2016-04-15 PT PT167188358T patent/PT3283107T/pt unknown
- 2016-04-18 TW TW111145063A patent/TW202335681A/zh unknown
- 2016-04-18 TW TW110123147A patent/TWI787880B/zh active
- 2016-04-18 TW TW105112037A patent/TWI733664B/zh active
- 2016-11-30 US US15/365,717 patent/US10512689B2/en active Active
-
2017
- 2017-09-27 PH PH12017501774A patent/PH12017501774A1/en unknown
- 2017-10-13 MX MX2022003572A patent/MX2022003572A/es unknown
- 2017-10-16 IL IL255072A patent/IL255072B/en unknown
- 2017-10-17 CL CL2017002636A patent/CL2017002636A1/es unknown
- 2017-11-10 CO CONC2017/0011536A patent/CO2017011536A2/es unknown
-
2018
- 2018-05-23 HK HK18106697.3A patent/HK1247099A1/zh unknown
-
2019
- 2019-12-20 US US16/723,854 patent/US11612654B2/en active Active
-
2020
- 2020-08-21 CY CY20201100783T patent/CY1123397T1/el unknown
- 2020-08-25 HR HRP20201334TT patent/HRP20201334T1/hr unknown
-
2021
- 2021-09-22 JP JP2021153809A patent/JP2022008479A/ja active Pending
-
2022
- 2022-01-03 IL IL289600A patent/IL289600A/en unknown
- 2022-06-10 AU AU2022204037A patent/AU2022204037A1/en active Pending
-
2023
- 2023-03-27 US US18/190,822 patent/US20240091354A1/en active Pending
- 2023-10-12 JP JP2023176705A patent/JP2024009946A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1247099A1 (zh) | 包含抗pd-1抗體和另外的抗體的組合的組合物 | |
IL258214A (en) | Antibodies - anti-pd-1 and preparations | |
IL282962A (en) | Anti-PD-1 antibodies and methods of using them | |
HK1254880A1 (zh) | 抗pd-1抗體及其應用 | |
IL265844A (en) | Anti-lag-3 antibodies and preparations | |
ZA201902265B (en) | Anti-pd-1 antibodies and their uses | |
IL262176A (en) | Anti-tim-3 antibodies and preparations | |
HK1248718A1 (zh) | 抗cd40抗體及其用途 | |
HK1253306A1 (zh) | 抗ntb-a抗體及相關組合物和方法 | |
HK1215870A1 (zh) | 種抗 的單克隆抗體及其獲得方法 | |
GB201612317D0 (en) | Antibody compositions | |
GB201502002D0 (en) | Uses and compositions | |
GB201502026D0 (en) | Uses and compositions | |
GB201501991D0 (en) | Uses and compositions | |
HK1258731A1 (zh) | Hiv抗體組合物和使用方法 | |
GB201511886D0 (en) | Uses and compositions | |
GB201502834D0 (en) | Composition of objects |